SCYNEXIS to Participate in Upcoming April Women’s Health
JERSEY Metropolis, N.J., April 04, 2022 (World NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to conquer and prevent challenging-to-address and drug-resistant infections, right now introduced participation in a few women’s well being conferences in April.
“As the creator of the first oral cure for vaginal yeast infection authorized in the Unites States in much more than 20 many years, our scientific groups are particularly happy to be at the forefront of analysis and growth for new groundbreaking treatment options in the underserved region of women’s health and fitness,” reported Marco Taglietti, M.D., President and Main Govt Officer of SCYNEXIS, “We glance forward to getting an option through these meetings to join health-related colleagues from close to the state to talk about and find out particulars about crucial breakthroughs in the discipline.”
Conferences:
American Faculty of Osteopathic Obstetricians and Gynecologists (ACOOG) 89th Once-a-year Convention
Concept: Moving Forward – Debates and Instructions in Women’s Well being
Date: April 3-8, 2022
Location: San Antonio
Occasion Information
National Black Nurse Practitioner Association (NBNPA) 3rd Yearly Academic Conference
Concept: Diversity and Inclusion in Health care – Its Impact on Individual Treatment
Day: April 29-30, 2022
Spot: Houston
Function Information and facts
Ms. Drugs Women’s Health and fitness Matters Convention
Concept: What is New in 2022 – CME Celebration
Date: April 28-30, 2022
Locale: Ft. Lauderdale, Fla.
Occasion Information
About BREXAFEMME® (ibrexafungerp tablets)
BREXAFEMME is a novel oral antifungal authorized for the procedure of vulvovaginal candidiasis (VVC), also recognised as vaginal yeast infection. Its mechanism of motion, glucan synthase inhibition, is fungicidal against Candida species, this means it kills fungal cells. The New Drug Application (NDA) for BREXAFEMME was permitted by the U.S. Food and Drug Administration (Food and drug administration) on June 1, 2021. The NDA was supported by beneficial outcomes from two Section 3, randomized, double-blind, placebo-managed, multi-center reports (VANISH-303 and VANISH-306), in which oral ibrexafungerp demonstrated efficacy and a favorable tolerability profile in females with VVC. BREXAFEMME represents the to start with permitted drug in a new antifungal class in about 20 yrs and is the initially and only procedure for vaginal yeast infections which is both of those oral and non-azole.
Indicator
BREXAFEMME is a triterpenoid antifungal indicated for the treatment method of grownup and postmenarchal pediatric ladies with vulvovaginal candidiasis (VVC).
DOSAGE AND ADMINISTRATION
The advised dosage of BREXAFEMME is 300 mg (two tablets of 150 mg) 2 times a day for just one day, for a total treatment dosage of 600 mg. BREXAFEMME may perhaps be taken with or with no foods.
Important Safety Data
- BREXAFEMME is contraindicated in the course of being pregnant and in patients with a heritage of hypersensitivity to ibrexafungerp
- BREXAFEMME administration during pregnancy may perhaps cause fetal harm dependent on animal experiments. Prior to initiating therapy, verify being pregnant position in women of reproductive possible and suggest them to use helpful contraception for the duration of treatment method
- When administering BREXAFEMME with powerful CYP3A inhibitors, the dose of BREXAFEMME ought to be minimized to 150 mg 2 times a working day for one working day. Administration of BREXAFEMME with robust CYP3A inducers should really be averted
- Most frequent adverse reactions noticed in scientific trials (incidence ≥2{ab24ffeec902ceefbc5fdafafd943b0c5d12b666e16ef1a5e7125e4fcd74f5fa}) were diarrhea, nausea, stomach soreness, dizziness, and vomiting
To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or Fda at 1-800-Fda-1088 or www.fda.gov/medwatch.
For far more details, visit www.brexafemme.com. Make sure you click here for Prescribing Information.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology organization groundbreaking modern medications to assistance millions of individuals all over the world conquer and stop hard-to-handle bacterial infections that are starting to be more and more drug-resistant. SCYNEXIS scientists are establishing the company’s direct asset, ibrexafungerp (previously known as SCY-078), as a wide-spectrum, systemic antifungal for several fungal indications in equally the group and clinic configurations. SCYNEXIS has initiated the launch of its initially commercial products in the U.S., BREXAFEMME® (ibrexafungerp tablets). The U.S. Food items and Drug Administration (Fda) permitted BREXAFEMME on June 1, 2021. In addition, late-phase scientific investigation of oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (VVC) and the therapy of daily life-threatening invasive fungal infections in hospitalized clients is ongoing. For more information and facts, visit www.scynexis.com.
Speak to:
Trader Relations
Irina Koffler
Controlling Director
LifeSci Advisors, LLC
646-970-4681
[email protected]
Media Relations
Gloria Gasaatura
LifeSci Communications
646-970-4688
[email protected]
